# A Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing Regimen

> **NCT00932373** · PHASE1 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 54 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** trastuzumab-MCC-DM1

## Key facts

- **NCT ID:** NCT00932373
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2015-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00932373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00932373, "A Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing Regimen". Retrieved via MORVS 2026-10-30 from https://api.morvs.ai/clinical/NCT00932373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*